Atorvastatin
Atorvastatin is a statin-class lipid-lowering drug used primarily to reduce low-density lipoprotein cholesterol and cardiovascular risk.
Atorvastatin is a statin-class lipid-lowering drug used primarily to reduce low-density lipoprotein cholesterol and cardiovascular risk. Like other statins, it acts by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering hepatic cholesterol production and increasing LDL receptor expression. Beyond its established role in dyslipidemia and atherosclerotic cardiovascular disease prevention, atorvastatin is also widely studied for pleiotropic effects related to inflammation, oxidative stress, endothelial function, and vascular remodeling.
In recent biomedical research, atorvastatin has been investigated not only as a cardiovascular therapy but also as a modulator of calcification, macrophage polarization, and cancer cell biology. The studies provided here examine its effects in plaque-relevant vascular and stromal cells, in atherosclerosis models, in spinal cord injury target prediction, and in colorectal cancer combination strategies with sorafenib or SREBP2 inhibitors. These contexts reflect interest in atorvastatin as a biologically active small molecule with potential effects extending beyond cholesterol lowering.
Where the papers sit
13 papers from the last 6 months study atorvastatin directly · updated from PubMed 3 Oct 2026
Study type 1 clinical trial · 2 observational · 2 human data · 8 preclinical
Themes no clear themes · 1 new direction
Those 13 do not share a common subject.
-
Formulation, cancer, cardiovascular, neurological, metabolic, and adverse-effect studies are grouped here without a shared biological question. Atorvastatin appears in nanoparticle, hydrogel, SNEDDS, and 3D-printed tablet work, as well as sorafenib or ezetimibe combinations. Other papers assess survival, behavior, QT interval, neuropathic symptoms, or Parkinson disease. The set supports no common therapeutic direction.
Atorvastatin emerges as a reproducible cause of perioral small-fibre neuropathic symptoms
The subject of the paper is a patient with perioral neuropathic symptoms during statin treatment. Against the set’s predominant use of atorvastatin as a therapeutic agent or experimental intervention, the report found that dryness, itching, numbness, and tingling around the mouth began after atorvastatin exposure, resolved after discontinuation, and recurred with repeat trials of both atorvastatin and rosuvastatin. This identifies atorvastatin not as a treatment being evaluated but as the suspected cause of a reversible small-fibre neuropathy, adding an adverse neurological role outside the other categories in the set 42637515Aug.
Papers
The 13 papers from the last 6 months that study atorvastatin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (13)
- Glutamine-tagged Sorafenib and Atorvastatin Coloaded Polymeric Nanoparticles for Hybrid Cell Death Induction in Colorectal Cancer: Part I Formulation, Characterization, In-vitro/In-vivo Safety and Efficacy Evaluation. AAPS PharmSciTech · 2 Oct 2026 PMID 42827216
- Direct Powder Extrusion of Atorvastatin 3D-Printed Tablets for Immediate-Release: Solid-State Characterization and Dissolution Performance. AAPS PharmSciTech · 10 Sept 2026 PMID 42717140
- Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease. Neurotoxicity research · 9 Sept 2026 PMID 42714756
- Deciphering the Mechanisms of Statin-Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data. CPT: pharmacometrics & systems pharmacology · 1 Sept 2026 PMID 42678094
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. The New England journal of medicine · 31 Aug 2026 PMID 42670961
- Atorvastatin Exerts Context-Dependent Metabolic and Beneficial Effects on Behavior and Apoptotic Signaling in a Cafeteria Diet-Induced Metabolic Dysfunction Model. Neurochemical research · 29 Aug 2026 PMID 42667336
- An uncommon side effect of statins: perioral neuropathic symptoms. BMJ case reports · 24 Aug 2026 PMID 42637515
- Atorvastatin-loaded frankincense self-nanoemulsifying drug delivery system (SNEDDS) thermoresponsive hydrogel enhances wound healing in an animal model. International journal of pharmaceutics · 1 Aug 2026 PMID 42542257
- Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. Fitoterapia · 15 Jun 2026 PMID 42297079
- Exploring Synergistic Potential of Sorafenib and Atorvastatin to Launch Apoptosis and Ferroptosis-driven Mixed Cell Death Mechanism in Colorectal Cancer. AAPS PharmSciTech · 27 May 2026 PMID 42204072
- Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. European journal of clinical pharmacology · 8 May 2026 PMID 42104119
- Screening macrophage polarization genes in spinal cord injury as therapeutic targets. PloS one · 4 May 2026 PMID 42081466
- Evaluation of Combined Treatment With Atorvastatin and SREBP2 Inhibitors Against Colorectal Cancer Cells Under Two-dimensional and Three-dimensional Culture Models. Anticancer research · 28 Apr 2026 PMID 42049373
By study type
Clinical trials (1)
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. The New England journal of medicine · 31 Aug 2026 PMID 42670961
Observational studies and case reports (2)
- An uncommon side effect of statins: perioral neuropathic symptoms. BMJ case reports · 24 Aug 2026 PMID 42637515
- Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. European journal of clinical pharmacology · 8 May 2026 PMID 42104119
Human data, design not indexed (2)
- Deciphering the Mechanisms of Statin-Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data. CPT: pharmacometrics & systems pharmacology · 1 Sept 2026 PMID 42678094
- Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. Fitoterapia · 15 Jun 2026 PMID 42297079
Preclinical: animal, cell and lab studies (8)
- Glutamine-tagged Sorafenib and Atorvastatin Coloaded Polymeric Nanoparticles for Hybrid Cell Death Induction in Colorectal Cancer: Part I Formulation, Characterization, In-vitro/In-vivo Safety and Efficacy Evaluation. AAPS PharmSciTech · 2 Oct 2026 PMID 42827216
- Direct Powder Extrusion of Atorvastatin 3D-Printed Tablets for Immediate-Release: Solid-State Characterization and Dissolution Performance. AAPS PharmSciTech · 10 Sept 2026 PMID 42717140
- Atorvastatin Shows Limited Disease-Modifying Effects in an A53T α-Synuclein Mouse Model of Parkinson's Disease. Neurotoxicity research · 9 Sept 2026 PMID 42714756
- Atorvastatin Exerts Context-Dependent Metabolic and Beneficial Effects on Behavior and Apoptotic Signaling in a Cafeteria Diet-Induced Metabolic Dysfunction Model. Neurochemical research · 29 Aug 2026 PMID 42667336
- Atorvastatin-loaded frankincense self-nanoemulsifying drug delivery system (SNEDDS) thermoresponsive hydrogel enhances wound healing in an animal model. International journal of pharmaceutics · 1 Aug 2026 PMID 42542257
- Exploring Synergistic Potential of Sorafenib and Atorvastatin to Launch Apoptosis and Ferroptosis-driven Mixed Cell Death Mechanism in Colorectal Cancer. AAPS PharmSciTech · 27 May 2026 PMID 42204072
- Screening macrophage polarization genes in spinal cord injury as therapeutic targets. PloS one · 4 May 2026 PMID 42081466
- Evaluation of Combined Treatment With Atorvastatin and SREBP2 Inhibitors Against Colorectal Cancer Cells Under Two-dimensional and Three-dimensional Culture Models. Anticancer research · 28 Apr 2026 PMID 42049373
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.